LT
LTRN.US Lantern Pharma Inc
- Market cap
- USD 6.47M
- P/E
- -
- P/B
- 9.74x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LTRN.US undervalued?
Graham numberThe Graham number of Lantern Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lantern Pharma Inc fundamental analysis
No fundamental analysis for Lantern Pharma Inc yet.
Lantern Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma …
Full company profileLantern Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lantern Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.54K | -1.63K | -3.39K | -97.4K | -155K | -175K | -190K | -17.3K | - |
| Operating Income | -1.73M | -2.43M | -5.91M | -12.6M | -14.4B | -17.9M | -22.2M | -18.0M | -13.8M |
| EBITDA | -1.73M | -2.43M | -5.90M | -12.4M | -14.3B | -15.9M | -20.8M | -17.1M | -20.8M |
| Net Income | -1.73M | -2.43M | -5.91M | -12.4M | -14.3B | -16.0M | -20.8M | -17.1M | -20.8M |
| EPS | -0.28 | -0.39 | -0.95 | -1.13 | -1,314 | -1.47 | -1.93 | -1.57 | -1.67 |
| Balance Sheet | |||||||||
| Total Assets | 450K | 1.43M | 20.4M | 74.0M | 58.8M | 43.6M | 25.6M | 11.0M | 8.60M |
| Total Liabilities | 652K | 489K | 661K | 2.38M | 2.80M | 2.74M | 4.38M | 4.50M | 11.8M |
| Shareholders' Equity | -202K | 943K | 19.7M | 71.6M | 56.0M | 40.9M | 21.2M | 6.53M | -3.22M |
| Cash & Short-term Investments | 445K | 1.23M | 19.2M | 70.7M | 55.2M | 41.3M | 24.0M | 10.1M | 7.36M |
| Total Debt | - | - | 109K | 205K | 52.9K | 234K | 244K | 78.5M | 39.7K |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.27M | -2.13M | -5.65M | -10.6M | -12.8M | -14.3M | -17.8M | -15.7M | -13.4M |
| Capital Expenditure | 5.72K | 5.72K | 16.1K | 15.5K | 27.8K | 18.7K | 12.6K | 1.72K | 6.00 |
| Free Cash Flow | -1.27M | -2.13M | -5.67M | -10.6M | -12.8M | -14.4M | -17.8M | -15.7M | -13.4M |
| Ratios | |||||||||
| ROE | - | -257.4% | -30.0% | -17.3% | -25,446.9% | -39.0% | -98.1% | -262.0% | - |
| ROA | -383.8% | -169.5% | -29.0% | -16.7% | -24,236.6% | -36.6% | -81.3% | -155.1% | -241.8% |
| Debt to Equity | - | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 12.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lantern Pharma Inc dividends
Lantern Pharma Inc has not paid dividends in the last 8 fiscal years.
Who owns Lantern Pharma Inc
- Insiders 18.16%
- Institutions 17.56%
- Public & others 64.28%
- Shares outstanding 14.9M
- Free float 10.7M
Top funds holding LTRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 338K | 2.27% | 0.00% | Sep 2026 |
| Abante Quant Value FI | 53.4K | 0.36% | +50.81% | Aug 2026 |
| Fidelity Extended Market Index | 49.2K | 0.33% | -0.37% | Sep 2026 |
| Horizon Kinetics Medical ETF | 22.7K | 0.15% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 17.5K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 15.3K | 0.10% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.36K | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 1.92K | 0.01% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 643.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding LTRN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Empery Asset Management, LP | 843K | 5.64% | 0.00% | Jun 2026 |
| CM Management, LLC | 500K | 3.35% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 425K | 2.85% | +28.02% | Jun 2026 |
| Renaissance Technologies Corp | 368K | 2.47% | +26.58% | Sep 2026 |
| BIOS CAPITAL MANAGEMENT, LP | 249K | 1.67% | -71.15% | Jun 2026 |
| Geode Capital Management, LLC | 103K | 0.69% | -7.91% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 50.0K | 0.33% | +0.69% | Jun 2026 |
| Citadel Advisors Llc | 47.9K | 0.32% | 0.00% | Jun 2026 |
| Westside Investment Management, Inc. | 47.9K | 0.32% | -4.40% | Jun 2026 |
| Quadrature Capital Limited | 39.6K | 0.27% | 0.00% | Jun 2026 |
| Goss Wealth Management LLC | 27.0K | 0.18% | -1.28% | Jun 2026 |
| Horizon Asset Management Inc/ny | 25.2K | 0.17% | -4.58% | Jun 2026 |
| Davenport & Company LLC | 23.8K | 0.16% | 0.00% | Jun 2026 |
| State Street Corp | 23.7K | 0.16% | 0.00% | Jun 2026 |
| BlackRock Inc | 22.4K | 0.15% | -50.63% | Jun 2026 |
| Bank of New York Mellon Corp | 21.3K | 0.14% | 0.00% | Jun 2026 |
| Northern Trust Corp | 17.5K | 0.12% | +12.16% | Jun 2026 |
| XTX Topco Ltd | 17.4K | 0.12% | 0.00% | Jun 2026 |
| UBS Group AG | 16.6K | 0.11% | +65.05% | Jun 2026 |
| The Colony Group LLC | 15.4K | 0.10% | 0.00% | Jun 2026 |
Lantern Pharma Inc company profile
- Company name
- Lantern Pharma Inc
- Ticker
- LTRN.US
- Exchange
- USA Stocks
- Listed since
- Jun 11, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 1920 McKinney Avenue, Dallas, TX, United States, 75201
- Phone
- 972 277 1136
- Website
- lanternpharma.com
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma Inc management
5- Mr. Panna SharmaPresident, CEO & Director · born 1971
- Mr. David R. MargraveCFO & Secretary · born 1961
- Dr. Kishor Gopaldas Bhatia Ph.D.Chief Scientific Officer & Scientific Consultant · born 1955
- Dr. Peter L. Nara D.V.M., M.S., Ph.D.Co-Founder & Advisor
- Dr. Marc C. Chamberlain M.D.Chief Medical Officer of Starlight Therapeutics